Results
1 -
5 of
5A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors, Cancer Chemotherapy and Pharmacology A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors, Investigational New Drugs Chemotherapy for Malignant Pleural Mesothelioma: Past, Present and Future, Current Pulmonology Reports FAK/PYK2 inhibitors defactinib and VS-4718 enhance immune checkpoint inhibitor efficacy, Journal for ImmunoTherapy of Cancer FAK-inhibition opens the door to checkpoint immunotherapy in Pancreatic Cancer, Journal for ImmunoTherapy of Cancer